Kidney Transplant Research Today is a free monthly online journal that collates and summarizes the latest research about Kidney Transplant, including details on risks, prognosis, procedure, surgery, organ donation.

Volume 2 (2005), Issue 5 (May)

1. Changes in quality of life after renal transplantation.
   Transplant Proc, 37(3): 1618-21. [Abstract] [Full-text]
2. Living donor kidney transplantation: impact of differentiated immunosuppressive regimen.
   Transplant Proc, 37(3): 1616-7. [Abstract] [Full-text]
3. Cyclosporine C2 levels in de novo renal allograft recipients: a German multicenter prospective observational study.
   Transplant Proc, 37(3): 1612-5. [Abstract] [Full-text]
4. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
   Transplant Proc, 37(3): 1608-11. [Abstract] [Full-text]
5. Relationship between donor factors, immunogenic up-regulation, and outcome after kidney transplantation.
   Transplant Proc, 37(3): 1605-7. [Abstract] [Full-text]
6. Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab.
   Transplant Proc, 37(3): 1601-4. [Abstract] [Full-text]
7. Cyclosporine-based immunosuppressive strategies for kidney recipients: interim analysis of German data from the Multinational Observational Study (MOST).
   Transplant Proc, 37(3): 1597-600. [Abstract] [Full-text]
8. Valsartan-induced hematocrit changes in renal transplant patients.
   Transplant Proc, 37(3): 1586-8. [Abstract] [Full-text]
9. C2 monitoring of cyclosporine in stable renal transplant patients results in lower costs and improved renal function.
   Transplant Proc, 37(3): 1583-5. [Abstract] [Full-text]
10. Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem.
    Transplant Proc, 37(3): 1580-2. [Abstract] [Full-text]
11. Impact of pregnancy on the function of transplanted kidneys.
    Transplant Proc, 37(3): 1577-9. [Abstract] [Full-text]
12. Hepatotoxicity associated with cyclosporine monitoring using C2 recommendations in adults renal recipients receiving ketoconazole.
    Transplant Proc, 37(3): 1574-6. [Abstract] [Full-text]
13. Plasmapheresis for the prophylaxis and treatment of recurrent focal segmental glomerulosclerosis following renal transplant.
    Transplant Proc, 37(3): 1473-4. [Abstract] [Full-text]
14. Markers of fibrosis in early biopsies of renal transplants.
    Transplant Proc, 37(3): 1468-70. [Abstract] [Full-text]
15. Lumbar bone mineral density after kidney transplantation: a three-year prospective study.
    Transplant Proc, 37(3): 1466-7. [Abstract] [Full-text]
16. Cost of renal transplant maintenance immunosuppression: effect of control of vascular risk factors.
    Transplant Proc, 37(3): 1464-5. [Abstract] [Full-text]
17. Treatment with adefovir dipivoxil in a renal transplant patient with renal insufficiency and lamivudine-resistant hepatitis B infection.
    Transplant Proc, 37(3): 1462-3. [Abstract] [Full-text]
18. Effect of parathyroidectomy on renal graft function.
    Transplant Proc, 37(3): 1459-61. [Abstract] [Full-text]
19. Antibodies against the donor antigen glutathione S-transferase T1 after renal transplantation.
    Transplant Proc, 37(3): 1457-8. [Abstract] [Full-text]
20. Kidney-pancreas transplants: is it so difficult to start a program?
    Transplant Proc, 37(3): 1455-6. [Abstract] [Full-text]
21. High initial blood levels of tacrolimus in overweight renal transplant recipients.
    Transplant Proc, 37(3): 1453-4. [Abstract] [Full-text]
22. Psychologic stages in renal transplant.
    Transplant Proc, 37(3): 1449-52. [Abstract] [Full-text]
23. Minimal model analysis in nondiabetic renal transplant recipients with hepatitis C.
    Transplant Proc, 37(3): 1446-8. [Abstract] [Full-text]
24. Pancreas islet transplantation in patients with type 1 diabetes mellitus after kidney transplantation.
    Transplant Proc, 37(3): 1443-5. [Abstract] [Full-text]
25. Effect of new immunosuppressive regimens on cost of renal transplant maintenance immunosuppression.
    Transplant Proc, 37(3): 1441-2. [Abstract] [Full-text]
26. Two doses of daclizumab with delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors >55 years of age.
    Transplant Proc, 37(3): 1438-40. [Abstract] [Full-text]
27. Basiliximab (Simulect) in renal transplantation with high risk for delayed graft function.
    Transplant Proc, 37(3): 1435-7. [Abstract] [Full-text]
28. Change in serum creatinine levels between 6 and 12 months and kidney graft survival: influence of proteinuria.
    Transplant Proc, 37(3): 1433-4. [Abstract] [Full-text]
29. Similar impact of slow and delayed graft function on renal allograft outcome and function.
    Transplant Proc, 37(3): 1431-2. [Abstract] [Full-text]
30. Modulation factors of oxidative status in stable renal transplantation.
    Transplant Proc, 37(3): 1428-30. [Abstract] [Full-text]
31. Evaluation of renal grafts in patients with lupus nephritis as cause of end-stage renal disease.
    Transplant Proc, 37(3): 1426-7. [Abstract] [Full-text]
32. Treatment of hepatitis C virus with interferon in hemodialysis patients awaiting kidney transplant.
    Transplant Proc, 37(3): 1424-5. [Abstract] [Full-text]
33. Role of poly-(ADP-ribose) polymerase in transplant acute tubular necrosis and its relationship with delayed renal function.
    Transplant Proc, 37(3): 1421-3. [Abstract] [Full-text]
34. Wisconsin and Celsior solutions in renal preservation: a comparative preliminary study.
    Transplant Proc, 37(3): 1419-20. [Abstract] [Full-text]
35. Comparison of pituitary-ovarian function in patients who have undergone successful renal transplantation and healthy women.
    Fertil Steril, 83(5): 1553-6. [Abstract] [Full-text]
36. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies.
    Lancet, 365(9470): 1570-6. [Abstract] [Full-text]
37. Looped silk tie: surgical technique for management of the renal vein during laparoscopic live-donor nephrectomy.
    J Endourol, 19(3): 401-5. [Abstract] [Full-text]
38. Accuracy of three-dimensional CT angiography for preoperative vascular evaluation of laparoscopic living renal donors.
    J Endourol, 19(3): 339-41. [Abstract] [Full-text]
39. Deep brain stimulation in a patient on immunosuppressive therapy after renal transplant.
    Parkinsonism Relat Disord, 11(4): 259-60. [Abstract] [Full-text]
40. Chronic allograft nephropathy and nephrotic range proteinuria.
    Clin Transplant, 19(3): 413-7. [Abstract] [Full-text]
41. United Network for Organ Sharing's expanded criteria donors: is stratification useful?
    Clin Transplant, 19(3): 406-12. [Abstract] [Full-text]
42. Risk factors for delayed kidney function and impact of delayed function on patient and graft survival in adult graft recipients.
    Clin Transplant, 19(3): 391-8. [Abstract] [Full-text]
43. Expanding the donor pool: use of renal transplants from non-heart-beating donors supported with extracorporeal membrane oxygenation.
    Clin Transplant, 19(3): 383-90. [Abstract] [Full-text]
44. Negative impact of 'old-to-old' donations on success of cadaveric renal transplants.
    Clin Transplant, 19(3): 372-6. [Abstract] [Full-text]
45. Safety of using hepatitis B virus core antibody or surface antigen-positive donors in kidney or pancreas transplantation.
    Clin Transplant, 19(3): 364-6. [Abstract] [Full-text]
46. Medicare-approved drug discount cards and renal transplant patients: how much can these cards reduce prescription costs?
    Clin Transplant, 19(3): 357-63. [Abstract] [Full-text]
47. Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients.
    Clin Transplant, 19(3): 340-5. [Abstract] [Full-text]
48. Outcome of microemulsion cyclosporine C2 concentration monitoring in kidney transplantation.
    Clin Transplant, 19(3): 335-9. [Abstract] [Full-text]
49. Early onset post-transplant lymphoproliferative disease is associated with allograft localization.
    Clin Transplant, 19(3): 327-34. [Abstract] [Full-text]
50. Outcome of renal transplants from pediatric donors <5 yr of age.
    Clin Transplant, 19(3): 316-20. [Abstract] [Full-text]
51. A calcineurin antagonist-free induction/maintenance strategy for immunosuppression in elderly recipients of renal allografts from elderly cadaver donors: long-term results from a prospective single centre trial.
    Clin Transplant, 19(3): 309-15. [Abstract] [Full-text]
52. Polyomavirus nephropathy after renal transplantation: a single centre experience.
    Nephrology (Carlton), 10(2): 198-203. [Abstract] [Full-text]
53. Routine insertion of ureteral stent in live-donor renal transplantation: is it worthwhile?
    Urology, 65(5): 867-71. [Abstract] [Full-text]
54. Laparoscopic live donor nephrectomy has equivalent early and late renal function outcomes compared with open donor nephrectomy.
    Urology, 65(5): 862-6. [Abstract] [Full-text]
55. Relevance of Toll-like receptor-4 polymorphisms in renal transplantation.
    Kidney Int, 67(6): 2454-61. [Abstract] [Full-text]
56. Access to, and outcome of, renal transplantation according to treatment modality of end-stage renal disease in France.
    Kidney Int, 67(6): 2448-53. [Abstract] [Full-text]
57. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients.
    Kidney Int, 67(6): 2440-7. [Abstract] [Full-text]
58. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation.
    Kidney Int, 67(6): 2415-21. [Abstract] [Full-text]
59. The advanced age deceased kidney donor: current outcomes and future opportunities.
    Kidney Int, 67(6): 2407-14. [Abstract] [Full-text]
60. The effect of a first kidney transplant on a subsequent transplant outcome: an experimental and clinical study.
    Kidney Int, 67(6): 2368-75. [Abstract] [Full-text]
61. Campath-1H use in pediatric renal transplantation.
    Am J Transplant, 5(6): 1569-73. [Abstract] [Full-text]
62. Heparin-induced thrombocytopenia in a renal transplant recipient.
    Am J Transplant, 5(6): 1537-40. [Abstract] [Full-text]
63. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis.
    Am J Transplant, 5(6): 1529-36. [Abstract] [Full-text]
64. Pre-donation assessment of kidneys by magnetic resonance angiography and venography: accuracy and impact on outcomes.
    Am J Transplant, 5(6): 1518-28. [Abstract] [Full-text]
65. En-bloc kidney transplantation in the United states: an analysis of united network of organ sharing (UNOS) data from 1987 to 2003.
    Am J Transplant, 5(6): 1513-7. [Abstract] [Full-text]
66. Preferences, knowledge, communication and patient-physician discussion of living kidney transplantation in African American families.
    Am J Transplant, 5(6): 1503-12. [Abstract] [Full-text]
67. Local complement C3 expression is upregulated in humoral and cellular rejection of renal allografts.
    Am J Transplant, 5(6): 1490-4. [Abstract] [Full-text]
68. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation.
    Am J Transplant, 5(6): 1483-9. [Abstract] [Full-text]
69. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies.
    Am J Transplant, 5(6): 1452-61. [Abstract] [Full-text]
70. Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients.
    Am J Transplant, 5(6): 1423-9. [Abstract] [Full-text]
71. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells.
    Am J Transplant, 5(6): 1415-22. [Abstract] [Full-text]
72. Long-term deterioration of kidney allograft function.
    Am J Transplant, 5(6): 1405-14. [Abstract] [Full-text]
73. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea.
    Am J Transplant, 5(6): 1383-91. [Abstract] [Full-text]
74. Increased expression of senescence-associated cell cycle inhibitor p16INK4a in deteriorating renal transplants and diseased native kidney.
    Am J Transplant, 5(6): 1375-82. [Abstract] [Full-text]
75. Epithelial to mesenchymal transition during late deterioration of human kidney transplants: the role of tubular cells in fibrogenesis.
    Am J Transplant, 5(6): 1367-74. [Abstract] [Full-text]
76. Association between mannose-binding lectin levels and graft survival in kidney transplantation.
    Am J Transplant, 5(6): 1361-6. [Abstract] [Full-text]
77. Clinical significance of an early protocol biopsy in living-donor renal transplantation: ten-year experience at a single center.
    Am J Transplant, 5(6): 1354-60. [Abstract] [Full-text]
78. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
    Am J Transplant, 5(6): 1347-53. [Abstract] [Full-text]
79. Steroid avoidance versus steroid withdrawal after simultaneous pancreas-kidney transplantation.
    Am J Transplant, 5(6): 1332-8. [Abstract] [Full-text]
80. Laparoscopic procurement of kidneys with multiple renal arteries is associated with increased ureteral complications in the recipient.
    Am J Transplant, 5(6): 1312-8. [Abstract] [Full-text]
81. MDRD equations for estimation of GFR in renal transplant recipients.
    Am J Transplant, 5(6): 1306-11. [Abstract] [Full-text]
82. Acute rejection after rat renal transplantation leads to downregulation of NA+ and water channels in the collecting duct.
    Am J Transplant, 5(6): 1276-85. [Abstract] [Full-text]
83. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis.
    Am J Transplant, 5(6): 1179-85. [Abstract] [Full-text]
84. Interleukin 18 (IL-18) upregulation in acute rejection of kidney allograft.
    Immunol Lett, 99(1): 30-5. [Abstract] [Full-text]
85. Recurrent IgA nephropathy after renal transplantation despite immunosuppressive regimens with mycophenolate mofetil.
    Nephrol Dial Transplant, 20(6): 1214-21. [Abstract] [Full-text]
86. Medication non-adherence in the adolescent renal transplant recipient: a clinician's viewpoint.
    Pediatr Transplant, 9(3): 398-407. [Abstract] [Full-text]
87. C0 or C2 driven cyclosporine monitoring in long-term pediatric kidney transplant recipients: is there any threat for chronic rejection development?
    Pediatr Transplant, 9(3): 328-31. [Abstract] [Full-text]
88. Recurrent urinary tract infection in the post-transplant reflux nephropathy patient: is reflux in the native ureter the culprit?
    Pediatr Transplant, 9(3): 324-7. [Abstract] [Full-text]
89. A randomized multicenter trial of OKT3 mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation.
    Pediatr Transplant, 9(3): 282-92. [Abstract] [Full-text]
90. Cytomegalovirus enhance expression of growth factors during the development of chronic allograft nephropathy in rats.
    Transpl Int, 18(6): 743-9. [Abstract] [Full-text]
91. Intraperitoneal catheter drainage of lymphocele: an outpatient procedure.
    Transpl Int, 18(6): 721-3. [Abstract] [Full-text]
92. The mechanism responsible for accommodation after living-related kidney transplantations across the blood barrier.
    Transpl Int, 18(6): 716-20. [Abstract] [Full-text]
93. Impact of cytokine gene polymorphism on cardiovascular risk in renal transplant recipients.
    Transpl Int, 18(6): 681-9. [Abstract] [Full-text]
94. Role of CXCR3 in cellular but not humoral renal allograft rejection.
    Transpl Int, 18(6): 676-80. [Abstract] [Full-text]
95. The effect of different immunosuppressive regimens on TGF-beta1 expression in kidney transplant patients.
    Transpl Int, 18(6): 668-71. [Abstract] [Full-text]
96. Gastrointestinal complications in renal transplant recipients.
    Transpl Int, 18(6): 643-50. [Abstract] [Full-text]
97. Quantitative PCR in the diagnosis of CMV infection and in the monitoring of viral load during the antiviral treatment in renal transplant patients.
    J Med Virol, 76(3): 367-72. [Abstract] [Full-text]
98. Multi-detector row CT in evaluation of 94 living renal donors by readers with varied experience.
    Radiology, 235(3): 905-10. [Abstract] [Full-text]
99. Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.
    Braz J Med Biol Res, 38(5): 683-94. [Abstract] [Full-text]
100. Detection and localization of proteinuria by dynamic contrast-enhanced magnetic resonance imaging using MS325.
     J Am Soc Nephrol, 16(6): 1752-7. [Abstract] [Full-text]
101. Prediction of acute renal allograft rejection by urinary monokine induced by IFN-gamma (MIG).
     J Am Soc Nephrol, 16(6): 1849-58. [Abstract] [Full-text]
102. Impact of cadaveric renal transplantation on survival in patients listed for transplantation.
     J Am Soc Nephrol, 16(6): 1859-65. [Abstract] [Full-text]
103. Viral infection in the renal transplant recipient.
     J Am Soc Nephrol, 16(6): 1758-74. [Abstract] [Full-text]
104. Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation.
     J Am Soc Nephrol, 16(6): 1839-48. [Abstract] [Full-text]
105. Protective effects of PG490-88 on chronic allograft rejection by changing intragraft gene expression profiles.
     Transplant Proc, 37(4): 1962-4. [Abstract] [Full-text]
106. Down-regulation of TGF-beta and VCAM-1 is associated with successful treatment of chronic rejection in rats.
     Transplant Proc, 37(4): 1926-8. [Abstract] [Full-text]
107. Gonadal function and immunosuppressive therapy after renal transplantation.
     Transplant Proc, 37(4): 1915-7. [Abstract] [Full-text]
108. Kaposi sarcoma in solid organ transplant recipients: a single center report.
     Transplant Proc, 37(4): 1905-9. [Abstract] [Full-text]
109. No increase in rejection or graft loss in kidney transplant recipients with thrombophilia treated with anticoagulation and triple immunosuppression.
     Transplant Proc, 37(4): 1902-4. [Abstract] [Full-text]
110. Do blood pressure and arterial wall properties change after conversion from cyclosporine to tacrolimus?
     Transplant Proc, 37(4): 1900-1. [Abstract] [Full-text]
111. Switching immunosuppression from cyclosporine to tacrolimus improves long-term kidney function: a 6-year study.
     Transplant Proc, 37(4): 1898-9. [Abstract] [Full-text]
112. Role of dietary salt intake in posttransplant hypertension with tacrolimus-based immunosuppression.
     Transplant Proc, 37(4): 1896-7. [Abstract] [Full-text]
113. Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy.
     Transplant Proc, 37(4): 1889-91. [Abstract] [Full-text]
114. Rheological properties of red blood cells in kidney transplant recipients: the role of lipid profile and type of immunosuppresion.
     Transplant Proc, 37(4): 1885-8. [Abstract] [Full-text]
115. Conversion from cyclosporine to tacrolimus results in improved creatinine but does not alter lipid profile.
     Transplant Proc, 37(4): 1877-9. [Abstract] [Full-text]
116. Improved attainment of NKF classified lipid target levels after conversion from cyclosporine to tacrolimus in renal graft recipients.
     Transplant Proc, 37(4): 1874-6. [Abstract] [Full-text]
117. Cardiovascular risk estimates and risk factors in renal transplant recipients.
     Transplant Proc, 37(4): 1868-70. [Abstract] [Full-text]
118. Incidence and risk factors of clinical characteristics, tacrolimus pharmacokinetics, and related genomic polymorphisms for posttransplant diabetes mellitus in the early stage of renal transplant recipients.
     Transplant Proc, 37(4): 1865-7. [Abstract] [Full-text]
119. Conversion from tacrolimus to cyclosporin is associated with a significant improvement of glucose metabolism in patients with new-onset diabetes mellitus after renal transplantation.
     Transplant Proc, 37(4): 1857-60. [Abstract] [Full-text]
120. Factors influencing the onset of diabetes mellitus after kidney transplantation: a single French center experience.
     Transplant Proc, 37(4): 1851-6. [Abstract] [Full-text]
121. Impact of steroid withdrawal on metabolic parameters in a series of 112 enteric/systemic-drained pancreatic transplants.
     Transplant Proc, 37(4): 1821-5. [Abstract] [Full-text]
122. Single-shot antithymocyte globuline and daclizumab induction in simultaneous pancreas and kidney transplant recipient: three-year results.
     Transplant Proc, 37(4): 1818-20. [Abstract] [Full-text]
123. Neoquadruple induction with antithymocyte globulin/azathioprine/cyclosporine/prednisolone in simultaneous pancreas and kidney transplant recipients: 8.5-year results.
     Transplant Proc, 37(4): 1815-7. [Abstract] [Full-text]
124. Splenic radiation and double-filtration plasmapheresis in crossmatch-positive live renal transplantation.
     Transplant Proc, 37(4): 1806-7. [Abstract] [Full-text]
125. Improved graft survival in ABO-incompatible living donor kidney transplantation.
     Transplant Proc, 37(4): 1804-5. [Abstract] [Full-text]
126. Successful results after 5 years of tacrolimus therapy in ABO-incompatible kidney transplantation in Japan.
     Transplant Proc, 37(4): 1800-3. [Abstract] [Full-text]
127. The cost of steroid-free protocols in primary cadaver kidney transplantation.
     Transplant Proc, 37(4): 1797-9. [Abstract] [Full-text]
128. Late steroid withdrawal for renal transplant recipients on tacrolimus and MMF is safe.
     Transplant Proc, 37(4): 1795-6. [Abstract] [Full-text]
129. Steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil: three-year results.
     Transplant Proc, 37(4): 1792-4. [Abstract] [Full-text]
130. Steroid withdrawal or steroid avoidance in renal transplant recipients: focus on tacrolimus-based immunosuppressive regimens.
     Transplant Proc, 37(4): 1789-91. [Abstract] [Full-text]
131. Steroid avoidance immunosuppression in low-risk kidney transplant recipients.
     Transplant Proc, 37(4): 1785-8. [Abstract] [Full-text]
132. Prognosis of HTLV-I-positive renal transplant recipients.
     Transplant Proc, 37(4): 1779-82. [Abstract] [Full-text]
133. sCD30 and neopterin as risk factors of chronic renal transplant rejection: impact of cyclosporine A, tacrolimus, and mycophenolate mofetil.
     Transplant Proc, 37(4): 1776-8. [Abstract] [Full-text]
134. Evaluation of daclizumab to reduce delayed graft function in non-heart-beating renal transplantation: a prospective, randomized trial.
     Transplant Proc, 37(4): 1774-5. [Abstract] [Full-text]
135. Improvement of quality of life in tacrolimus-based pediatric renal transplant recipients and their caregivers, including donors.
     Transplant Proc, 37(4): 1771-3. [Abstract] [Full-text]
136. Successful treatment of 115 pediatric renal transplant recipients with tacrolimus-based immunosuppressive therapy: a 7-year multicenter study in Japan.
     Transplant Proc, 37(4): 1769-70. [Abstract] [Full-text]
137. Long-term results of tacrolimus therapy for renal transplantation in patients with diabetic nephropathy in Japan.
     Transplant Proc, 37(4): 1767-8. [Abstract] [Full-text]
138. Safety analysis after tacrolimus immunosuppression in renal transplant recipients in Japan: 5-year results in >1500 patients.
     Transplant Proc, 37(4): 1764-6. [Abstract] [Full-text]
139. Cytokine polymorphisms do not influence acute rejection in renal transplantation under tacrolimus-based immunosuppression.
     Transplant Proc, 37(4): 1760-1. [Abstract] [Full-text]
140. The pathologic impact of tacrolimus on protocol biopsy in renal transplant patients with basiliximab-based immunosuppression.
     Transplant Proc, 37(4): 1757-9. [Abstract] [Full-text]
141. The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation.
     Transplant Proc, 37(4): 1751-3. [Abstract] [Full-text]
142. Differential effects of cyclosporine and tacrolimus on mycophenolate pharmacokinetics in patients with impaired kidney function.
     Transplant Proc, 37(4): 1748-50. [Abstract] [Full-text]
143. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters.
     Transplant Proc, 37(4): 1745-7. [Abstract] [Full-text]
144. Determination of cyclosporine and its metabolites in blood via HPLC-MS and correlation to clinically important parameters.
     Transplant Proc, 37(4): 1741-4. [Abstract] [Full-text]
145. Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients.
     Transplant Proc, 37(4): 1736-8. [Abstract] [Full-text]
146. Tacrolimus monitoring in renal transplantation: a comparison between high-performance liquid chromatography and immunoassay.
     Transplant Proc, 37(4): 1733-5. [Abstract] [Full-text]
147. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
     Transplant Proc, 37(4): 1730-2. [Abstract] [Full-text]
148. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy.
     Transplant Proc, 37(4): 1725-7. [Abstract] [Full-text]
149. A model for scoring and grading willingness of a potential living related donor.
     J Med Ethics, 31(6): 338-40. [Abstract] [Full-text]
150. Transmission of an undiagnosed sarcoma to recipients of kidney and liver grafts procured in a non-heart beating donor.
     Liver Transpl, 11(6): 696-9. [Abstract] [Full-text]
151. Randomized clinical trial of daclizumab induction and delayed introduction of tacrolimus for recipients of non-heart-beating kidney transplants.
     Br J Surg, 92(6): 681-7. [Abstract] [Full-text]

© 2004-2008 Kidney Transplant Research Today. All Rights Reserved.